Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Neurology

Journal Scan / Research · July 27, 2023

Efficacy of Donanemab in Patients With Early Symptomatic Alzheimer Disease

JAMA: The Journal of the American Medical Association


Additional Info

Disclosure statements are available on the authors' profiles:

JAMA: The Journal of the American Medical Association
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 2023 Jul 17;[EPub Ahead of Print], JR Sims, JA Zimmer, CD Evans, M Lu, P Ardayfio, J Sparks, AM Wessels, S Shcherbinin, H Wang, ES Monkul Nery, EC Collins, P Solomon, S Salloway, LG Apostolova, O Hansson, C Ritchie, DA Brooks, M Mintun, DM Skovronsky

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading